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Abstract
Plasmid-mediated and chromosomally-encoded colistin resistance is increasingly being reported worldwide. We aimed to
determine the prevalence of faecal carriage of colistin-resistant Gram-negative rod isolates in a university hospital in
western France. From February to May 2016, rectal swabs from 653 patients hospitalized in various clinical settings were
recovered and subsequently screened for colistin resistance using the SuperPolymyxin medium. Antimicrobial
susceptibilities were determined according to EUCAST guidelines. Genetic detection of plasmid-mediated colistin resistance
was performed by PCR. The faecal carriage with intrinsic colistin-resistant isolates was high (23%), while the faecal carriage
with Gram-negative rods showing acquired resistance was low (1.4%). No isolate carried the plasmid-mediated mcr-1/mcr-2
genes. It was noteworthy that none of the patients carrying isolates with acquired colistin resistance had previously received
a colistin-based treatment, while these isolates were not multidrug resistant.
Plasmid-mediated mcr-1 [1] and mcr-2 genes [2] conferring
colistin resistance in Enterobacteriaceae have been discov-
ered recently in animals worldwide. Simultaneously, human
infections and faecal carriage with Enterobacteriaceae
isolates carrying the mcr-1 gene were reported extensively
during 2015 [3]. In France, a high prevalence of the plas-
mid-borne mcr-1 gene has been reported among extended-
spectrum ß-lactamase (ESBL)-producing Escherichia coli
isolates collected from the faeces of diarrheic veal calves [4].
This finding may suggest that the dissemination of mcr-1
from animals to humans may have already occurred quite
extensively.
We therefore conducted a prospective study to evaluate the
prevalence of faecal carriage of acquired and intrinsic colis-
tin-resistant Gram-negative rods among patients admitted
to or hospitalized at the Pellegrin University Hospital of
Bordeaux (1350 beds), which is the largest public hospital in
south-west France. From February to May 2016, rectal
swabs from 653 patients hospitalized in various clinical
settings (emergency, intensive care unit, surgery, medical
units) were screened. Colistin-resistant isolates were
screened using the SuperPolymyxin medium, which con-
tains colistin sulfate at a concentration of 3.5mg l1, allow-
ing the isolation of any colistin-resistant Gram-negative
rods [5]. Colonies growing on this medium were identified
using a MALDI-TOF mass spectrometer (Brüker, Champs-
sur-Marne, France). Isolates belonging to species that are
intrinsically resistant to colistin were not further investi-
gated. Minimum inhibitory concentrations (MICs) of
colistin were determined for the other isolates using the ref-
erence broth microdilution (BMD) method. The results
were interpreted according to the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) guidelines,
2016 [6]. All colistin-resistant isolates were subsequently
screened for the mcr-1 and mcr-2 genes by PCR, as
described previously [1, 2].
Out of the 653 rectal swabs, 150 gave isolates that are known
to be intrinsically resistant species, namely Proteus sp.
(n=75), Morganella sp. (n=22), Providencia sp. (n=12),
Serratia sp. (n=6) and Hafnia sp. (n=35) [the latter genus
was recently described as being naturally resistant to colistin
(A. Jayol, personal communication)].
Nine isolates with an acquired colistin trait were recovered,
including three Escherichia coli, two Klebsiella pneumoniae,
one Raoultella ornithinolytica, two Enterobacter cloacae and
one Stenotrophomonas maltophilia (Table 1). The MIC val-
ues of colistin ranged from 4 to 128mg l1 for those isolates
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that exhibited various profiles of resistance to the other anti-
biotics (Table 1). Only two isolates (a single K. pneumoniae
and a single E. cloacae) were multidrug resistant and pro-
duced an extended-spectrum ß-lactamase. All those isolates
were negative for the mcr-1 and mcr-2 genes. The two colis-
tin-resistant E. cloacae isolates presented ‘skip wells’ with
the BMD method, suggesting a heteroresistant phenotype.
These isolates could belong to a cluster-dependent colistin-
heteroresistant complex, as described recently [7].
Out of the nine patients carrying an acquired colistin-
resistance trait, five were hospitalized in an intensive care
unit, and two were from the community. None of the
patients had previously received a colistin-based treatment,
further highlighting the occurrence of colistin-resistant iso-
lates without obvious corresponding antibiotic selection, as
previously notified by Olaitan et al [8].
This prospective study indicates a high prevalence (23%) of
faecal carriage with intrinsic colistin-resistant Gram-nega-
tive rods, but a low prevalence (1.4 %) with isolates showing
acquired resistance. No isolate carried the plasmid-mediated
mcr-1 and mcr-2 genes, suggesting that there is currently
low diffusion of these resistance determinants among
human clinical samples. Similar observations were recently
made during hospital- and community-based surveys in
Switzerland [9]. However, single E. coli and K. pneumoniae
isolates with a plasmid-borne mcr-1 gene were isolated in
2016 from clinical infections in our hospital (A. Jayol, per-
sonal communication). Both isolates were ESBL producers
and the E. coli one was recovered from a patient without a
recent history of travel. Regular screening of plasmid-medi-
ated colistin resistance, which is now quite easy to imple-
ment owing to the availability of a selective medium
(SuperPolymyxin), may now be important to monitor and
therefore possibly detect at an early stage the emergence of
colistin-resistant isolates, with the ultimate goal of prevent-
ing their further spread in France.
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Table 1. Colistin-resistant Enterobacteriaceae isolates
Species MIC of CS (mg l1) Additional antibiotic resistances ESBL Unit
E. coli 4 AMX, TIC, SXT No Emergency
E. coli 4 AMX, TIC, FQ, GM No Surgery ICU
E. coli 8 AMX, C1G No Neurosurgery ICU
K. pneumoniae 64 FQ, SXT No Medical ICU
K. pneumoniae 32 AMX, TIC, C3G, C4G, FQ, FSF, FT, GM, SXT Yes Surgery
R. ornithinolytica 16 No No Gastroenterology
E. cloacae 64 AMX, TIC, C3G, C4G, FT, GM, SXT Yes Medical ICU
E. cloacae 8 FT No Emergency
S. maltophilia 128 / No Medical ICU
AMX, amoxicillin; C1G, first-generation cephalosporin; C3G, third-generation cephalosporin; C4G, fourth-generation cephalosporin; CS, colistin; ESBL,
extended-spectrum beta-lactamase; FQ, fluoroquinolone; FSF, fosfomycin; FT, nitrofurantoin; GM, gentamicin; ICU, intensive care unit; SXT, co-trimox-
azole; TIC, ticarcillin.
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